BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Tantai XX, Yang LB, Wei ZC, Xiao CL, Chen LR, Wang JH, Liu N. Association of proton pump inhibitors with risk of hepatic encephalopathy in advanced liver disease: A meta-analysis. World J Gastroenterol 2019; 25(21): 2683-2698 [PMID: 31210719 DOI: 10.3748/wjg.v25.i21.2683]
URL: https://www.wjgnet.com/1007-9327/full/v25/i21/2683.htm
Number Citing Articles
1
Naina Mohamed Pakkir Maideen. Adverse Effects Associated with Long-Term Use of Proton Pump InhibitorsChonnam Medical Journal 2023; 59(2): 115 doi: 10.4068/cmj.2023.59.2.115
2
Akira Sakamaki, Kenya Kamimura, Takeshi Yokoo, Akihiko Osaki, Seiichi Yoshikawa, Yoshihisa Arao, Toru Setsu, Hiroteru Kamimura, Nobuo Waguri, Manabu Takeuchi, Kazuhiro Funakoshi, Shuji Terai. The prognosis and incidence of hepatic encephalopathy of patients with liver cirrhosis treated with proton pump inhibitorsMedicine 2021; 100(32): e26902 doi: 10.1097/MD.0000000000026902
3
Jun Sik Yoon, Ji Hoon Hong, Soo Young Park, Seung Up Kim, Hwi Young Kim, Ju Yeon Kim, Moon Haeng Hur, Min Kyung Park, Yun Bin Lee, Han Ah Lee, Gi‐Ae Kim, Dong Hyun Sinn, Sung Jae Park, Youn Jae Lee, Yoon Jun Kim, Jung‐Hwan Yoon, Jeong‐Hoon Lee. High‐dose proton pump inhibitor treatment is associated with a higher mortality in cirrhotic patients: A multicentre studyAlimentary Pharmacology & Therapeutics 2024; 59(8): 973 doi: 10.1111/apt.17909
4
Igor G. Bakulin, Inna A. Oganezova, Maria I. Skalinskaya, Ekaterina V. Skazyvaeva. Liver cirrosis and complication risk managementTerapevticheskii arkhiv 2021; 93(8): 963 doi: 10.26442/00403660.2021.08.200917
5
Pan Zhang, Lizhi Zhou, Li Chen, Zhen Zhang, Rui Han, Gangwen Guo, Haocheng Zhou. Electroencephalography Signatures for Hepatic Encephalopathy in Cirrhosis Patients Treated with Proton Pump Inhibitors: An Exploratory Pilot StudyBiomedicines 2022; 10(12): 3040 doi: 10.3390/biomedicines10123040
6
Agastya Patel, Piotr Spychalski, Jarek Kobiela. Letter: mind the gap – search and publication date of systematic reviews and meta‐analysisAlimentary Pharmacology & Therapeutics 2021; 54(5): 730 doi: 10.1111/apt.16537
7
Yun Su, Yueqiao Chen, Jinghui Zheng, Chun Yao. Association between proton pump inhibitors and risk of hepatic encephalopathy in patients undergoing transjugular intrahepatic portosystemic shunt: a protocol for a systematic review and meta-analysisBMJ Open 2024; 14(4): e078412 doi: 10.1136/bmjopen-2023-078412
8
Florent Broca, Mylène Dufrenoy, Mickaël Martin. Prise en charge de l’encéphalopathie hépatique : revue généraleLa Revue de Médecine Interne 2024;  doi: 10.1016/j.revmed.2024.10.007
9
Rui Dai, Alan A. Sag, Jonathan G. Martin, Nicholas T. Befera, Waleska M. Pabon-Ramos, Paul V. Suhocki, Tony P. Smith, Charles Y. Kim, Andrew J. Muir, James Ronald. Proton pump inhibitor use is associated with increased rates of post-TIPS hepatic encephalopathy: Replication in an independent patient cohortClinical Imaging 2021; 77: 187 doi: 10.1016/j.clinimag.2021.04.034
10
Ummi Maimunah, Andreas Agung Kurniawan, Andrio Palayukan. Adverse Effects of Long-term Proton Pump Inhibitors in Chronic Liver Disease Patients – A Preliminary Article ReviewReview of Clinical Pharmacology and Pharmacokinetics - International Edition 2024; 38(1): 87 doi: 10.61873/WWAY6273
11
Yuan Bin Liu, Ming Kai Chen. The impact of proton pump inhibitors in liver diseases and the effects on the liverJournal of Digestive Diseases 2022; 23(4): 196 doi: 10.1111/1751-2980.13093
12
Rok Orel, Marc A. Benninga, Ilse J. Broekaert, Frederic Gottrand, Alexandra Papadopoulou, Carmen Ribes-Koninckx, Mike Thomson, Michael Wilschanski, Nikhil Thapar. Drugs in Focus: Proton Pump InhibitorsJournal of Pediatric Gastroenterology & Nutrition 2021; 72(5): 645 doi: 10.1097/MPG.0000000000003063
13
K. Toda. Are proton pump inhibitors suitable medicines to prevent upper gastrointestinal events due to non-steroidal anti-inflammatory drugs?Osteoarthritis and Cartilage 2020; 28(1): e1 doi: 10.1016/j.joca.2019.09.010
14
Carlos Martín de Argila de Prados, Julia Lopez Cardona, Federico Argüelles-Arias. Safe use of proton-pump inhibitorsRevista Española de Enfermedades Digestivas 2023; 115 doi: 10.17235/reed.2023.9834/2023
15
Xiaoli Wu, Daofu Zhang, Yuexiao Yu, Lianqing Lou, Xiaofei Li. Proton pump inhibitor use and mortality in patients with cirrhosis: a meta-analysis of cohort studiesBioscience Reports 2020; 40(6) doi: 10.1042/BSR20193890
16
Reidar Fossmark, Tom C. Martinsen, Helge L. Waldum. Adverse Effects of Proton Pump Inhibitors—Evidence and PlausibilityInternational Journal of Molecular Sciences 2019; 20(20): 5203 doi: 10.3390/ijms20205203
17
Haijuan Yao, Hongyu Li, Zhuang Ma, Yanyan Wu, Yufu Tang, Hao Meng, Hao Yu, Chengfei Peng, Yue Teng, Quanyu Zhang, Tianyi Zhu, Haitao Zhao, Guiyang Chu, Zhenhua Tong, Lu Liu, Hui Lu, Xingshun Qi. Impact of proton pump inhibitors on the in-hospital outcome of COVID-19 patients: a retrospective studyTherapeutic Advances in Gastroenterology 2022; 15 doi: 10.1177/17562848221104365
18
A.M. Osadchuk, I.D. Loranskaya, M.A. Osadchuk, L.R. Khamatnurova. Proton pump inhibitors: positive and negative properties. On the 45th anniversary of their discoveryRussian Journal of Preventive Medicine 2024; 27(11): 135 doi: 10.17116/profmed202427111135
19
Gasser El-Azab. Proton Pump Inhibitors in Patients with Cirrhosis: Pharmacokinetics, Benefits and DrawbacksCurrent Gastroenterology Reports 2024; 26(12): 323 doi: 10.1007/s11894-024-00943-7
20
Maria de Brito Nunes, Matthias Knecht, Reiner Wiest, Jaume Bosch, Annalisa Berzigotti. Predictors and management of post‐banding ulcer bleeding in cirrhosis: A systematic review and meta‐analysisLiver International 2023; 43(8): 1644 doi: 10.1111/liv.15621